CSIMarket Company Name, Ticker, Suppliers, else..
 
Psyence Biomedical ltd   (NASDAQ: PBM)
 
Price: $4.3400 $0.13 3.088%
Day's High: $4.399899959564209 Week Perf: 1.64 %
Day's Low: $ 4.10 30 Day Perf: 36.91 %
Volume (M): 26,329 52 Wk High: $ 216.41
Volume (M$): $ 0 52 Wk Avg: $38.66
Open: $4.22 52 Wk Low: $1.92



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Pacific Booker Minerals Inc is a Canadian mining company that focuses on exploring and developing mineral properties. The company is primarily focused on its Morrison copper-gold project located in British Columbia, Canada. Pacific Booker Minerals is committed to responsible and sustainable mining practices, which includes working closely with local communities and adhering to strict environmental regulations. The company is dedicated to maximizing shareholder value through the efficient exploration and development of its mineral properties.


   Company Address: 121 Richmond Street West Toronto 0 ON
   Company Phone Number: 346-7764   Stock Exchange / Ticker: NASDAQ PBM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Psyence Groups NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Published Tue, Mar 25 2025 2:48 PM UTC

Psyence Biomedical Strengthens Its Scientific Advisory Board with Renowned Psychopharmacologist Dr. Dan J. Stein Amidst Ongoing ChallengesIn a strategic move aimed at enhancing its research capabilities, Psyence Group Inc. (Psyence Group) has announced a significant appointment to the Scientific Advisory Board of its NASDAQ-listed associate, Psyence Biomedical Ltd. (NASDAQ:...
Clinical Study

Psyence Biomedical Advances Phase IIb Clinical Trial Amidst Market Challenges,

Published Sun, Dec 29 2024 12:26 PM UTC

Psyence Biomedical Ltd. has recently made significant strides in advancing its active Phase IIb clinical trial, focusing on the exploration of potential therapeutic applications. The company has announced that patient screening is currently underway, with expectations set for the first patient to be randomized into the study as early as January 2024. This milestone is an ess...
Stock Market Announcement

Doubling Valuation of PsyLabs Offers Fresh Hope for Psyence Biomedical Amidst Dramatic Market Challenges

Published Tue, Dec 3 2024 12:30 PM UTC

In a remarkable turn of events, a recent independent valuation has appraised PsyLabs, a subsidiary of Psyence Biomedical Ltd, at approximately $2 million. This valuation represents a significant doubling of its stake value, which had previously been much lower. The news has sparked a wave of optimism among shareholders, providing a glimmer of hope in what has been a tumultuo...
Shares

Psyence Biomedicals Nasdaq Lifeline: A Second Chance to Defy Market Odds,

Published Wed, Nov 20 2024 12:30 PM UTC

In a significant development for Psyence Biomedical Ltd. (Nasdaq: PBM), the company has cleared a substantial hurdle regarding its listing on the Nasdaq exchange. On November 20, 2024, Psyence announced that it received a favorable decision from the Nasdaq Hearings Panel after a hearing held on October 31, 2024. This outcome allows Psyence to continue trading on the exchange...
Stock Market Announcement

Psyence Biomedical Ltd. Announces Effective Date for 1-for-75 Share Consolidation in Response to Market Challenges and Strategic Shift,

Published Tue, Nov 19 2024 9:05 PM UTC

Psyence Biomedical Ltd. Announces Effective Date for 1-for-75 Share Consolidation Amidst Recent Challenges and Strategic MovesIn a critical announcement on November 19, 2024, Psyence Biomedical Ltd. (Nasdaq: PBM), a company specializing in nature-derived psychedelics for mental health applications, declared the effective date for its previously approved share consolidation. ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 238.59
Price to Sales (Expected) -
Price to Book 0.01
PEG (TTM) -

Financial Strength Current
Quick Ratio 23.53
Working Capital Ratio 23.53
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -29185.94 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) 35.21 $
Cash 188.65 $
Book Value 313.12 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,314,236
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.